
Robert A. Vetere
Examiner (ID: 7087, Phone: (571)270-1864 , Office: P/1712 )
| Most Active Art Unit | 1712 |
| Art Unit(s) | 1792, 1712 |
| Total Applications | 1040 |
| Issued Applications | 588 |
| Pending Applications | 102 |
| Abandoned Applications | 387 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20406409
[patent_doc_number] => 20250375518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-11
[patent_title] => ALLERGEN DESENSITIZATION METHOD
[patent_app_type] => utility
[patent_app_number] => 19/302265
[patent_app_country] => US
[patent_app_date] => 2025-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19302265
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/302265 | ALLERGEN DESENSITIZATION METHOD | Aug 17, 2025 | Pending |
Array
(
[id] => 20406409
[patent_doc_number] => 20250375518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-12-11
[patent_title] => ALLERGEN DESENSITIZATION METHOD
[patent_app_type] => utility
[patent_app_number] => 19/302265
[patent_app_country] => US
[patent_app_date] => 2025-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19302265
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/302265 | ALLERGEN DESENSITIZATION METHOD | Aug 17, 2025 | Pending |
Array
(
[id] => 20048113
[patent_doc_number] => 20250186335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE
[patent_app_type] => utility
[patent_app_number] => 19/053879
[patent_app_country] => US
[patent_app_date] => 2025-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19053879
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/053879 | LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE | Feb 13, 2025 | Pending |
Array
(
[id] => 20048113
[patent_doc_number] => 20250186335
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-06-12
[patent_title] => LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE
[patent_app_type] => utility
[patent_app_number] => 19/053879
[patent_app_country] => US
[patent_app_date] => 2025-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9824
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19053879
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/053879 | LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE | Feb 13, 2025 | Pending |
Array
(
[id] => 19989491
[patent_doc_number] => 20250127713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-24
[patent_title] => LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE
[patent_app_type] => utility
[patent_app_number] => 19/001141
[patent_app_country] => US
[patent_app_date] => 2024-12-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10074
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19001141
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/001141 | LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYE | Dec 23, 2024 | Pending |
Array
(
[id] => 19990816
[patent_doc_number] => 20250129038
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-24
[patent_title] => INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE
[patent_app_type] => utility
[patent_app_number] => 18/920501
[patent_app_country] => US
[patent_app_date] => 2024-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8594
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18920501
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/920501 | Inhibitors of extracellular signal-regulated kinase | Oct 17, 2024 | Issued |
Array
(
[id] => 19982763
[patent_doc_number] => 20250120985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => METHOD OF TREATING DIABETIC MACULAR EDEMA
[patent_app_type] => utility
[patent_app_number] => 18/917928
[patent_app_country] => US
[patent_app_date] => 2024-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12006
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18917928
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | Oct 15, 2024 | Pending |
Array
(
[id] => 19982763
[patent_doc_number] => 20250120985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-17
[patent_title] => METHOD OF TREATING DIABETIC MACULAR EDEMA
[patent_app_type] => utility
[patent_app_number] => 18/917928
[patent_app_country] => US
[patent_app_date] => 2024-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12006
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18917928
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/917928 | METHOD OF TREATING DIABETIC MACULAR EDEMA | Oct 15, 2024 | Pending |
Array
(
[id] => 19554779
[patent_doc_number] => 20240366571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/775105
[patent_app_country] => US
[patent_app_date] => 2024-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27947
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 237
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18775105
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/775105 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | Jul 16, 2024 | Pending |
Array
(
[id] => 19554779
[patent_doc_number] => 20240366571
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/775105
[patent_app_country] => US
[patent_app_date] => 2024-07-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27947
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 237
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18775105
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/775105 | MODULATORS OF SK4 POTASSIUM CHANNEL AND USES THEREOF | Jul 16, 2024 | Pending |
Array
(
[id] => 19432431
[patent_doc_number] => 20240300929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/603489
[patent_app_country] => US
[patent_app_date] => 2024-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12611
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18603489
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/603489 | 1-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASES | Mar 12, 2024 | Pending |
Array
(
[id] => 19969670
[patent_doc_number] => 12338262
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-06-24
[patent_title] => Modulators of TNF-alpha activity
[patent_app_type] => utility
[patent_app_number] => 18/594725
[patent_app_country] => US
[patent_app_date] => 2024-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62154
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18594725
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/594725 | Modulators of TNF-alpha activity | Mar 3, 2024 | Issued |
Array
(
[id] => 19216342
[patent_doc_number] => 20240181046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-06
[patent_title] => ALLERGEN DESENSITIZATION METHOD
[patent_app_type] => utility
[patent_app_number] => 18/441930
[patent_app_country] => US
[patent_app_date] => 2024-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7781
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18441930
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/441930 | Allergen desensitization method | Feb 13, 2024 | Issued |
Array
(
[id] => 19496407
[patent_doc_number] => 20240335425
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISION
[patent_app_type] => utility
[patent_app_number] => 18/439468
[patent_app_country] => US
[patent_app_date] => 2024-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23667
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18439468
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/439468 | PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISION | Feb 11, 2024 | Abandoned |
Array
(
[id] => 19541605
[patent_doc_number] => 20240358641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE
[patent_app_type] => utility
[patent_app_number] => 18/432404
[patent_app_country] => US
[patent_app_date] => 2024-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18432404
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/432404 | PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USE | Feb 4, 2024 | Pending |
Array
(
[id] => 19065620
[patent_doc_number] => 20240100046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => DEGRADANT COMPOUND IN A MEDICAMENT
[patent_app_type] => utility
[patent_app_number] => 18/535520
[patent_app_country] => US
[patent_app_date] => 2023-12-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20728
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18535520
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/535520 | DEGRADANT COMPOUND IN A MEDICAMENT | Dec 10, 2023 | Abandoned |
Array
(
[id] => 19065583
[patent_doc_number] => 20240100009
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => CARBACHOL FORMULATIONS TO ENHANCE ANTI-PRESBYOPIA EFFECTS
[patent_app_type] => utility
[patent_app_number] => 18/531082
[patent_app_country] => US
[patent_app_date] => 2023-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16207
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531082
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/531082 | Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effects | Dec 5, 2023 | Issued |
Array
(
[id] => 19387804
[patent_doc_number] => 20240277674
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE
[patent_app_type] => utility
[patent_app_number] => 18/500416
[patent_app_country] => US
[patent_app_date] => 2023-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18500416
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/500416 | OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE | Nov 1, 2023 | Abandoned |
Array
(
[id] => 19170854
[patent_doc_number] => 20240156828
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => OCULAR PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/497962
[patent_app_country] => US
[patent_app_date] => 2023-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34236
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18497962
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/497962 | OCULAR PHARMACEUTICAL COMPOSITIONS | Oct 29, 2023 | Abandoned |
Array
(
[id] => 19246673
[patent_doc_number] => 20240197657
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN
[patent_app_type] => utility
[patent_app_number] => 18/494341
[patent_app_country] => US
[patent_app_date] => 2023-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4473
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18494341
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/494341 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN | Oct 24, 2023 | Abandoned |